98 related articles for article (PubMed ID: 21805446)
1. Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.
Lee JA; Cochran BJ; Lobov S; Ranson M
Semin Thromb Hemost; 2011 Jun; 37(4):395-407. PubMed ID: 21805446
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor type 2: still an enigmatic serpin but a model for gene regulation.
Medcalf RL
Methods Enzymol; 2011; 499():105-34. PubMed ID: 21683251
[TBL] [Abstract][Full Text] [Related]
3. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.
Medcalf RL; Stasinopoulos SJ
FEBS J; 2005 Oct; 272(19):4858-67. PubMed ID: 16176260
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
Lobov S; Croucher DR; Saunders DN; Ranson M
Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
[TBL] [Abstract][Full Text] [Related]
5. Evidence for intracellular cleavage of plasminogen activator inhibitor type 2 (PAI-2) in normal epidermal keratinocytes.
Risse BC; Chung NM; Baker MS; Jensen PJ
J Cell Physiol; 2000 Feb; 182(2):281-9. PubMed ID: 10623892
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
[TBL] [Abstract][Full Text] [Related]
7. The enigma PAI-2. Gene expression, evolutionary and functional aspects.
Bachmann F
Thromb Haemost; 1995 Jul; 74(1):172-9. PubMed ID: 8578452
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
Zhou HM; Bolon I; Nichols A; Wohlwend A; Vassalli JD
Cancer Res; 2001 Feb; 61(3):970-6. PubMed ID: 11221892
[TBL] [Abstract][Full Text] [Related]
9. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
10. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Reilly TM; Mousa SA; Seetharam R; Racanelli AL
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
[TBL] [Abstract][Full Text] [Related]
11. The ovine plasminogen activator inhibitors type 1 and type 2 cDNAs: molecular cloning, characterization and expression in various tissues.
Theodorou G; Bizelis I; Rogdakis E; Politis I
Gene; 2010 Apr; 454(1-2):20-30. PubMed ID: 20114071
[TBL] [Abstract][Full Text] [Related]
12. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
13. The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis.
Dickinson JL; Norris BJ; Jensen PH; Antalis TM
Cell Death Differ; 1998 Feb; 5(2):163-71. PubMed ID: 10200461
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
15. PZP and PAI-2: Structurally-diverse, functionally similar pregnancy proteins?
Wyatt AR; Cater JH; Ranson M
Int J Biochem Cell Biol; 2016 Oct; 79():113-117. PubMed ID: 27554634
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the biological roles of PAI2 (SERPINB2) in cancer.
Croucher DR; Saunders DN; Lobov S; Ranson M
Nat Rev Cancer; 2008 Jul; 8(7):535-45. PubMed ID: 18548086
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal upregulation of urokinase plasminogen activator and its inhibitor, PAI-2, by Borrelia burgdorferi affects bacterial penetration and host-inflammatory response.
Haile WB; Coleman JL; Benach JL
Cell Microbiol; 2006 Aug; 8(8):1349-60. PubMed ID: 16882037
[TBL] [Abstract][Full Text] [Related]
19. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.
Wind T; Hansen M; Jensen JK; Andreasen PA
Biol Chem; 2002 Jan; 383(1):21-36. PubMed ID: 11928815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
